Sticking With CDK4/6 Inhibitors for Breast Cancer Wins in Post-Progression Setting

(MedPage Today) -- Patients with advanced estrogen receptor (ER)-positive breast cancer that progressed on CDK4/6 inhibitors had better survival if they continued CDK4/6 inhibition plus endocrine therapy rather than switch to endocrine therapy...